Niveus Medical is a Palo Alto medtech startup that has developed an electrode-based device to stimulate muscles and counteract disuse atrophy in immobile patients. The device has received FDA marketing clearance. The company is raising $3.6M, according to regulatory filings, to advance the technology; it previously raised $2M in 2011 from a syndicate including Band of Angels, Life Science Angels, Sand Hill Angels and others. Niveus positions the technology as a way to shorten hospital and ICU stays by keeping patients' muscles engaged even when sedentary. The company intends to initially target the roughly 1.8 million U.S. ICU patients with stays longer than five days and cites a conservative U.S. revenue opportunity exceeding $1.2B. Additional opportunities outside the ICU are envisioned, and the device lists indications including maintaining knee range of motion, preventing quadriceps disuse atrophy, muscle re-education, relaxing muscle spasms, and increasing local blood circulation. Niveus Medical is a Palo Alto, Calif.–based developer of a series of technologies aimed at reducing or preventing debilitation to accelerate patient recovery and shorten hospital stays. The company is developing a technology specifically to preserve muscle strength during long periods of sedation and bed rest. Led by CEO Brian J. Fahey, Niveus positions its products to reduce both hospital and payer costs. The company raised approximately $2m in Series A funding to support its operations. Management intends to use the proceeds to validate the benefits of its technology. No revenue or user metrics were disclosed in the article.

Total raised

$6M

Funding rounds

2

Latest round

Equity

Latest activity

Aug 2014